Newly Identified Marker Helps Predict Tuberculosis Complications in HIV Patients

"An NIAID study suggests that the increased frequency of an immune cell called CD14++CD16- monocyte is a strong indicator that a patient with HIV and tuberculosis (TB) may develop complications from anti-HIV drugs. For unclear reasons, a subset of people with both HIV and TB experience worsening of their TB symptoms after starting antiretroviral therapy (ART) to treat HIV. The study, which appears in the October 2, 2014, issue of PLOS Pathogens, offers a better understanding of why this may occur." Visit the NIAID website to read the complete article.